CardiaMetrics develops implantable medical devices equipped with subcutaneous sensors that continuously monitor hemodynamic and electrophysiological data to prevent cardiac decompensation in patients with chronic heart failure. This technology enables healthcare professionals to receive actionable insights for timely therapeutic adjustments, reducing hospital admissions and enhancing patient autonomy.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with chronic heart failure or those undergoing cardiotoxic cancer treatments require frequent monitoring to prevent cardiac decompensation, but current methods often lack the efficiency and reliability needed for proactive intervention. The increasing prevalence of heart failure and associated hospitalizations contribute to a significant economic burden on healthcare systems.
Solution
CardiaMetrics develops implantable medical devices featuring subcutaneous sensors that continuously collect hemodynamic and electrophysiological data, providing early detection of cardiac decompensation. This IoT-enabled solution aggregates and analyzes vital physiological data, delivering actionable insights to telemedicine platforms and physicians for personalized patient monitoring. By identifying and prioritizing patients at risk, CardiaMetrics enables timely therapeutic adjustments, reduces avoidable hospital admissions, and enhances the efficiency of healthcare teams. The system facilitates proactive management, helping to maintain cardiac condition stability and improve patient outcomes.
Target Audience
The primary target audience includes telemedicine platforms and healthcare professionals, specifically cardiologists and physicians, focused on managing patients with chronic heart failure or those at risk due to cardiotoxic treatments.
Features
- Subcutaneous sensors for continuous, multimodal monitoring of electrical and mechanical cardiac signals
- Daily data collection and aggregation of hemodynamic and electrophysiological parameters
- Wireless data transmission to remote monitoring platforms
- Integration of artificial intelligence for early detection of cardiac decompensation, up to 30 days in advance
- Biomarker translation for reliable and consistent remote monitoring
- Patient prioritization based on risk to optimize healthcare team efforts